CELLSIGHT TECHNOLOGIES, INC.
Doing business as CELLSIGHT TECHNOLOGIES INC
- SAN FRANCISCO, CA 94107-9107
- cellsighttech.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $2M
- Awards on record
- 1
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
CELLSIGHT TECHNOLOGIES, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About CELLSIGHT TECHNOLOGIES, INC.
- Headquarters
- SAN FRANCISCO, CA 94107-9107
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIE3UQXACGFR43
- CAGE5T0V1
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $2M
- Awards on record
- 1
- Top funding agencies
- National Institutes of Health
Awards
75N91022C00015
Completed: Period of performance ended Sep 15, 2026SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES
Department of Health and Human Services · National Institutes of Health
- Obligated
- $2M
- Period of performance
- Sep 16, 2022 – Sep 15, 2026
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75N91022C00015 SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES | Department of Health and Human Services · National Institutes of Health | 541715 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $2M | Sep 16, 2022 – Sep 15, 2026 | Completed: Period of performance ended Sep 15, 2026 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 7 awards
- Total awarded
- $7,254,593
- By phase
- SBIR Phase II: 4
- SBIR Phase I: 3
- By agency
- Department of Health and Human Services: 7
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2022: 1
- 2019: 1
- 2018: 1
- 2017: 1
- 2013: 1
- 2011: 1
Awards (most recent first)
Imaging intracerebral and systemic T cell immunity in patients with Alzheimer's disease using 18F-F-AraG
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $871,261
Sep 20, 2025 – Aug 19, 2028
- Active
Solicitation PAS22-196 (2022) · Topic NIA
SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,995,174
Solicitation PHS-2019-1 (2018) · Topic 396
SBIR PHASE I TOPIC 396 EVALUATION OF [18F]F-ARAG, A T CELL-SPECIFIC PET AGENT, AS AN IMAGING BIOMARKER PREDICTIVE OF RESPONSE TO IMMUNOTHERAPIES - MOONSHOT
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $300,000
Solicitation year 2018 · Topic NCI
Topic 376: A noninvasive PET imaging strategy for longitudinal monitoring of immune contexture in the tumor microenvironmen
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $299,641
Solicitation year 2017 · Topic NCI
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $2,040,978
Sep 21, 2017 – Aug 31, 2019
- Direct to Phase II
Solicitation PAR14-088 (2014) · Topic 102
SBIR TOPIC 307: NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER DI
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $1,499,971
Solicitation year 2013 · Topic NCI · Research partner: Stub
TAS::75 0849::TAS SBIR TOPIC 307 PHASE I NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER DIAGNOSIS, STAGING, AND
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $247,568
Solicitation year 2011 · Topic NCI · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with CELLSIGHT TECHNOLOGIES, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
